𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

✍ Scribed by Peter E. Schwartz; Joseph T. Chambers; Ernest I. Kohorn; Setsuko K. Chambers; Hervey Weitzman; Irene M. Voynick; Neil Maclusky; Frederick Naftolin

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
536 KB
Volume
63
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Advanced ovarian carcinoma: A prospectiv
Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)
✍ J. Carmo-Pereira; F. Oliveira Costa; Elvira Henriques; J. Almeida Ricardo πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 367 KB πŸ‘ 2 views

Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently. Objective responses were seen in

Luteinizing hormone-releasing hormone ag
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial
✍ GΓΌnter Emons; Olaf Ortmann; Hanns-Martin Teichert; Horst Fassl; Udo LΓΆhrs; Stig πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 908 KB

## Background: Several lines of evidence suggest that the proliferation of ovarian carcinoma might be stimulated by gonadotrophins. a number of phase i/phase ii clinical trials have reported that the suppression of endogenous luteinizing hormone and follicle-stimulating hormone secretion by luteini